Unknown

Dataset Information

0

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.


ABSTRACT: Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for close monitoring during initiation and ramp up, to reduce the risk of tumor lysis syndrome. The patient's risk should be assessed before the initiation of venetoclax. Appropriate management strategies should be used, including uricosuric agents, hydration, and routine laboratory monitoring, per guidelines. With early identification, immediate management, and dose adjustments, we suggest that tumor lysis syndrome and other toxicities, such as neutropenia and infections, with venetoclax-based treatment can be dealt with successfully.

SUBMITTER: Fischer K 

PROVIDER: S-EPMC7727567 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.

Fischer Kirsten K   Al-Sawaf Othman O   Hallek Michael M  

Hematology. American Society of Hematology. Education Program 20201201 1


Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for clo  ...[more]

Similar Datasets

| S-EPMC5679833 | biostudies-literature
| S-EPMC7154710 | biostudies-literature
| S-EPMC3845832 | biostudies-literature
| S-EPMC5437733 | biostudies-literature
| S-EPMC7107002 | biostudies-literature
| S-EPMC6859801 | biostudies-literature
| S-EPMC5820258 | biostudies-literature
| S-EPMC6879312 | biostudies-literature
| S-EPMC6237462 | biostudies-literature
| S-EPMC5922273 | biostudies-literature